JP2024535766A5 - - Google Patents

Info

Publication number
JP2024535766A5
JP2024535766A5 JP2024515310A JP2024515310A JP2024535766A5 JP 2024535766 A5 JP2024535766 A5 JP 2024535766A5 JP 2024515310 A JP2024515310 A JP 2024515310A JP 2024515310 A JP2024515310 A JP 2024515310A JP 2024535766 A5 JP2024535766 A5 JP 2024535766A5
Authority
JP
Japan
Prior art keywords
rna
particles
lipid
phospho
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535766A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/075168 external-priority patent/WO2023036960A1/en
Publication of JP2024535766A publication Critical patent/JP2024535766A/ja
Publication of JP2024535766A5 publication Critical patent/JP2024535766A5/ja
Pending legal-status Critical Current

Links

JP2024515310A 2021-09-10 2022-09-09 治療に適した脂質ベースのrna製剤 Pending JP2024535766A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2021074976 2021-09-10
EPPCT/EP2021/074976 2021-09-10
PCT/EP2022/075168 WO2023036960A1 (en) 2021-09-10 2022-09-09 Lipid-based rna formulations suitable for therapy

Publications (2)

Publication Number Publication Date
JP2024535766A JP2024535766A (ja) 2024-10-02
JP2024535766A5 true JP2024535766A5 (enExample) 2025-09-18

Family

ID=83594138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515310A Pending JP2024535766A (ja) 2021-09-10 2022-09-09 治療に適した脂質ベースのrna製剤

Country Status (5)

Country Link
US (1) US20240408032A1 (enExample)
EP (1) EP4398882A1 (enExample)
JP (1) JP2024535766A (enExample)
CN (1) CN118265522A (enExample)
WO (1) WO2023036960A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022115645A1 (en) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
AU2023413766A1 (en) 2022-12-23 2025-05-29 Biontech Delivery Technologies Gmbh Composition
WO2024193827A1 (en) * 2023-03-23 2024-09-26 BioNTech SE Stabilized nucleic acid compositions and methods for preparing, storing and using the same
WO2025021277A1 (en) * 2023-07-21 2025-01-30 BioNTech SE Agents and methods for targeted delivery of cytokines to immune cells
CN118001254B (zh) * 2024-04-09 2024-07-26 北京悦康科创医药科技股份有限公司 靶向抗原呈递细胞的脂质组合物及其应用
WO2026017917A1 (en) * 2024-07-19 2026-01-22 Ethris Gmbh Rnas with reduced ribosomal frameshift expression products

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP2186528B1 (en) * 2007-08-06 2014-03-19 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
CN107028886A (zh) * 2009-11-04 2017-08-11 不列颠哥伦比亚大学 含有核酸的脂质粒子及相关的方法
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
SI3445850T1 (sl) 2016-04-22 2021-12-31 BioNTech SE Postopki za zagotavljanje enoverižne RNA
WO2022115645A1 (en) * 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use

Similar Documents

Publication Publication Date Title
JP2024535766A5 (enExample)
US12453739B2 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
JP7236525B2 (ja) CFTR mRNA組成物ならびに関連する方法及び使用
US20220411791A1 (en) Nuclease Resistant Polynucleotides and Uses Thereof
EP3628335B1 (en) Lipidic nanoparticles for mrna delivery in the lungs
US12070509B2 (en) Nucleic acids and methods of treatment for cystic fibrosis
JP6463810B2 (ja) mRNA送達のための脂質ナノ粒子組成物および方法
JP2024533865A5 (enExample)
JP7774615B2 (ja) 大型rnaの脂質ナノ粒子封入
US20140294940A1 (en) Mrna therapy for urea cycle disorders
US12564645B2 (en) Methods for treatment of methylmalonic acidemia
JP2011507534A5 (enExample)
JP7789103B2 (ja) 原発性線毛機能不全症の治療のための組成物および方法
AU2022381750A1 (en) Lipid formulations containing nucleic acids and methods of treatment for cystic fibrosis
JP2025501764A5 (enExample)
CN113908288A (zh) 一种mRNA递送系统及其制备方法和应用
JP2025501905A (ja) イオン化脂質、脂質ナノ粒子、及びこれらの使用
KR20240066978A (ko) 핵산 약물의 경폐전달을 위한 지질나노입자 제형 및 이의 활용